{
    "nct_id": "NCT04754399",
    "official_title": "Phase 2 Trial of Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias",
    "inclusion_criteria": "* Postmenopausal according to standard clinical criteria OR receiving concomitant LHRH agonist therapy.\n* Taking aromatase inhibitor therapy (anastrozole, exemestane, or letrozole) for adjuvant treatment of breast cancer or for chemoprevention for at least 3 weeks and no more than 2 years at the time of enrollment.\n* Planning to take the same AI therapy for at least 15 weeks.\n* New or worsening joint pain and/or myalgias since starting the AI therapy.\n* Completion of surgery (mastectomy or lumpectomy/partial mastectomy) for treatment of breast cancer at least 3 months prior to enrollment.\n* The complete list of inclusion criteria is provided in the protocol.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic breast cancer.\n* Planned surgery during the 15-week study period.\n* Clinically significant laboratory abnormalities.\n* Use of cannabidiol, THC, or marijuana (oral, inhaled, or topical) within the 6 weeks prior to enrollment.\n* History of or currently has suicidal ideation or attempted suicide.\n* History of seizure other than febrile seizures in childhood.\n* The complete list of exclusion criteria is provided in the protocol.",
    "miscellaneous_criteria": ""
}